Shares of Novan, Inc. [NASDAQ: NOVN] skyrocketed 90.15% as it gained +8.31 at the time of writing on Friday. The strong performance of the firm has highlighted the positive sentiments of the investors after the firm disclosed positive topline efficacy and safety results for the B-SIMPLE4 pivotal Phase 3 clinical study of SB206.
It has been revealed that in line with outcomes from the Phase 2 and earlier Phase 3 studies of the firm, SB206 was discovered to be secure and well-tolerated. No treatment-related serious adverse events (TEAE) have been reported. B-SIMPLE4 is a multi-center, double-blind, randomized, vehicle-controlled study that topped its registration target by randomizing 891 sufferers in the study, across 55 clinical sites.
In addition to this, the sufferers were receiving treatment for more than 12 weeks with a follow-up visit at Week 24. The primary endpoint for the study is the percentage of sufferers with the complete approval of all curable molluscum lesions at Week 12. The firm has reported a trading volume of 12.91 million at the time of writing.
The positive results from B-SIMPLE4 signify a revolutionary achievement for its employees, investors, and even more importantly, people living with molluscum. The firm disclosed that the strong safety and statistically significant efficacy results give the firm self-assurance as its move forward in preparing an NDA to possibly bring SB206 to market and to sufferers in need of effective therapy.